Skip to main content Skip to main navigation menu Skip to site footer

Exploring rutinoside's impact on inflammation in a rat knee OA model induced by monosodium iodoacetate (MIA)


Link of Video Abstract:


Introduction: Osteoarthritis (OA) is a common joint disease characterized by persistent inflammation and cartilage breakdown. Monosodium iodoacetate (MIA) is often used to generate OA in rats. This study aims to explore the anti-inflammatory benefits of rutinoside, a natural flavonoid glycoside, in rats with MIA-induced knee OA.

Methods: The male Wistar rats were divided into five groups (n = 6) and randomly allocated to one of five treatments: control, OA, rutinoside, glucosamine sulfate, and sodium diclofenac-treated group. 3 mg of monosodium iodoacetate (MIA) was injected intra-articularly into the knee joints of rats to induce osteoarthritis. Rutinoside, glucosamine sulfate, and sodium diclofenac were given daily for four weeks. Body weight, joint swelling, knee bend score, interleukin-1 (IL-1) levels, interleukin-8 (IL-8) levels, and C-terminal telopeptide type II collagen (CTX-II) levels were all assessed.

Result: Rutinoside significantly decreased body weight loss, joint edema, and knee bend test scores compared to the untreated OA group. Furthermore, rutinoside was equally effective as glucosamine sulfate and sodium diclofenac in these parameters. The rutinoside, glucosamine sulfate, and sodium diclofenac groups had significantly lower IL-1, IL-8, and CTX-II levels than the untreated OA group.

Conclusion: Rutinoside reduced inflammatory responses, lowered joint edema, and improved knee bend test scores in a rat model of MIA-induced osteoarthritis. Its efficacy in preventing illness was comparable to glucosamine sulfate and sodium diclofenac. More study is needed to better understand rutinoside's underlying mechanisms and long-term consequences for treating osteoarthritis.


  1. He Y, Li Z, Alexander PG, Ocasio-Nieves BD, Yocum L, Lin H, Tuan RS. Pathogenesis of osteoarthritis: Risk factors, regulatory pathways in chondrocytes, and experimental models. Biology (Basel). 2020;9(8):194.
  2. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017;19:18.
  3. Ferraz CR, Carvalho TT, Manchope MF, Artero NA, Rasquel-Oliveira FS, Fattori V, et al. Therapeutic potential of flavonoids in pain and inflammation: Mechanisms of action, pre-clinical and clinical data, and pharmaceutical development. Molecules. 2020;25(3):762.
  4. Salehi B, Machin L, Monzote L, Sharifi-Rad J, Ezzat SM, Salem MA, et al. Therapeutic potential of quercetin: New insights and perspectives for human health. ACS Omega. 2020;5(20):11849–72.
  5. Negreanu-Pirjol BS, Oprea OC, Negreanu-Pirjol T, Roncea FN, Prelipcean AM, Craciunescu O, et al. Health benefits of antioxidant bioactive compounds in the fruits and leaves of Lonicera caerulea L. and Aronia melanocarpa (Michx.) Elliot. Antioxidants. 2023;12(4):951.
  6. Ganeshpurkar A, Saluja AK. The pharmacological potential of rutin. Saudi Pharm J. 2017;25(2):149–64.
  7. Ma Z, Du B, Li J, Yang Y, Zhu F. An insight into anti-inflammatory activities and inflammation related diseases of anthocyanins: A review of both in vivo and in vitro investigations. Int J Mol Sci. 2021;22(20):11076.
  8. Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004;96(3):229–45.
  9. Fitzpatrick LR, Woldemariam T. Small-Molecule Drugs for the Treatment of Inflammatory Bowel Disease. In: Comprehensive Medicinal Chemistry III. 2017. p. 495–510.
  10. Daghestani HN, Kraus VB. Inflammatory biomarkers in osteoarthritis. Osteoarthr Cartil. 2015;23(11):1890–6.
  11. Chow YY, Chin KY. The role of inflammation in the pathogenesis of osteoarthritis. Mediators Inflamm. 2020;8293921.
  12. Kim JR, Yoo JJ, Kim HA. Therapeutics in osteoarthritis based on an understanding of its molecular pathogenesis. Int J Mol Sci. 2018;19(3):674.
  13. Cheng H, Hao B, Sun J, Yin M. C-Terminal cross-linked telopeptides of type II collagen as biomarker for radiological knee osteoarthritis: A meta-analysis. Cartilage. 2020;11(4):512–20.
  14. Bihlet AR, Byrjalsen I, Bay-Jensen AC, Andersen JR, Christiansen C, Riis BJ, et al. Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis. Arthritis Res Ther. 2019;21:203.
  15. Löfvall H, Katri A, Dąbrowska A, Karsdal MA, Luo Y, He Y, et al. GPDPLQ1237—A type II collagen neo-epitope biomarker of osteoclast- and inflammation-derived cartilage degradation in vitro. Sci Rep. 2019;9:3050.

How to Cite

Normasari, R., Purwanto, B. ., & Tinduh, D. (2023). Exploring rutinoside’s impact on inflammation in a rat knee OA model induced by monosodium iodoacetate (MIA) . Bali Medical Journal, 13(1), 106–109.




Search Panel